Lessons Learned in Pathology and Oncology From the COVID-19 Pandemic
Targeted Oncology is proud to partner with the American Society of Clinical Pathology to present a 1-hour webinar with an expert panel, moderated by Dan Milner, MD, MSc, MBA.
During a live event, Amy Cummings, MD, discussed a patient case of a 69-year-old man with non–small cell lung cancer and an HER2 exon 20 insertion mutation.
The FDA accepted a BLA with priority review for sonesitatug vedotin in previously treated CLDN18.2-positive gastric/GEJ cancer based on OS data from CLARITY-Gastric01.
FDA approval of pimicotinib adds another CSF1R inhibitor for tenosynovial giant cell tumor, says Andrew J. Wagner, MD, PhD, of Dana-Farber Cancer Institute.
The November 2026 prescribing information removes the limitation that previously excluded patients with primary or secondary central nervous system lymphoma from the therapy’s large B-cell lymphoma indications.
During a live event, Zahra Kelly, DO, and participants discussed how drug interactions, tolerability in men in their 70s and beyond, and cost shape the choice among androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.
The designation supports development of elticertinib for patients with EGFR exon 20 insertion–mutated NSCLC progressing after platinum-based chemotherapy and amivantamab.